After Roche acquired Genentech Inc. and focused its attention largely on oncology drugs, Jim Wu, a US-trained biochemist who returned to China to work for Roche, saw opportunities in the Swiss drug maker's antiviral pipeline.
Wu who was a director at the Roche R&D center in Shanghai, founded a start-up in 2014, Ark Biosciences...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
